Balzar

Discussion in 'Sanofi' started by 8in, Nov 30, 2017 at 11:15 AM.

  1. 8in

    8in New Member

    Joined:
    Nov 30, 2017
    Messages:
    1
    Likes Received:
    0
    So is it true Balzar took the package?
     

  2. anonymous

    anonymous Guest

    Don't kid yourself; executive employment contracts have much more lucrative severance provisions than what they give the peons. Why take a watered down package when you have an air-tight contract for much more.
     
  3. anonymous

    anonymous Guest

    Exactly! And their pay is heavily weighted to salary, stock options and executive perks, which is exactly why they dont give a rats ass if your sales goals are attainable. Has little bearing on them if you dont get paid out, and can actually pad their pay if expenses are lower than budgeted.
     
  4. anonymous

    anonymous Guest

    Why does it seem like exactly no one gives a shit about what is happening here? It is dead quiet, they are silently stalking different divisions and showering them with pink slips and everyone is wondering who is next. This is the worst I have seen here and I have seen plenty. They need to start talking. Something is up.
     
  5. anonymous

    anonymous Guest

    The slaughter is coming.
     
  6. anonymous

    anonymous Guest

    Why do you think they would care? Have they ever cared? The french hate the sales force. You are nothing but dirt on the bottom of their shoe. So, now why do you care? You are a slave worker. They are about to release the shackles and chains from your ankles. Be free, proud and empowered.
     
  7. anonymous

    anonymous Guest

    What is up is declining pricing power across the portfolio. Most of the blockbuster drugs, like Lantus, have gone off patent and new drugs that are still patented are not competitive, like Praluent. When the sales line shrinks, the expense line must soon shrink as well if the company is to remain profitable.

    If sales could plug the hole in profitability Sanofi would be expanding the sales force. However, given the product line up we have to work with, the most talented sales people in the world cannot offset the profit bleed. Cuts are coming, and they will be especially big this time. There is not a damn thing you can do to avoid what is coming so have a Plan B in place. Sanofi is not the first large pharma to go through this, and they will not be the last as the industry continues to change.
     
  8. anonymous

    anonymous Guest

    Thanks that was a great recap of business 101. Nonetheless, sanofi is extremely top heavy in Middle Management. The cuts will be deepest in Management and dwindling divisions such as LTC and Hospital.
     
  9. anonymous

    anonymous Guest

    The cuts need to come from everywhere; the field, home office, all levels of management, manufacturing, distribution, you name it. Crunch time has arrived and nobody, nobody, should be immune from the fallout.
     
  10. anonymous

    anonymous Guest

    Look around the field is bare. We are at low levels now across the country. Some managers have zero reps. Unless we go back to one rep per territory like 1998 not going to be huge layoffs. They’ve accomplished their task through attrition. Yes their will be cuts, huge noooo.
     
  11. anonymous

    anonymous Guest

    Winter is coming.
     
  12. anonymous

    anonymous Guest

    You know nothing John Snow.
     
  13. anonymous

    anonymous Guest

    Management won't escape unscathed this time. Kaplan's layoff last year reeked of incompetence. Does it make sense for an ABL to have 4 people reporting to them? RBL and VP's and ABL's have always been protected. This one is going to be deep. All jobs that don't generate revenue will be gone. LTC, hospital jobs, Regional Acct managers, CEM team all will be shown the door. This one their be no life rafts or favoritism. Degenerate behavior won't be tolerated. Kaplan did extensive damage with his last debacle. Middle management is on the list this year. If you are in a nonrevenue job and you don't have Plan B you've nobody to blame. Your friends won't save you as they will be gone . You know who you are.
     
  14. anonymous

    anonymous Guest

    Much has changed since Kaplan. VP and RBL trying to show off to leaders that there geniuses. Most couldn't work in a car wash or tollbooth. God help this company.
     
  15. anonymous

    anonymous Guest

    Just keep talking about "the in-between". How can you go wrong? The "in-between" is like the force.
     
  16. anonymous

    anonymous Guest

    Word is Sanofi will be divesting their insulins OR just simply selling off their Diabetes BU. If you didn't take the package you may WISH you did. SMH....
     
  17. anonymous

    anonymous Guest

    I highly doubt it. Even while losing revenue. The great Glargiine brings in Billions, and Toujeo is close to hitting a billion. God loves the Cash Cow.
     
  18. anonymous

    anonymous Guest

    Lovenox is still cranking without any reps
     
  19. anonymous

    anonymous Guest

    Agree on Lovenox but not many generics with price significantly less. There will be cuts but not total slaughter of reps. We’ve already been slaughtered. Team of 2 in my geography is feasible
     
  20. anonymous

    anonymous Guest

    heard we would relaunch LovenoxXR with hospital division. Look for February launch meeting in Vegas.